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THE RECOGNITION that after transplantation resi-dent bone marrow-derived cells migrate out of the 
graft into the recipient has led to an increasing acceptance 
that the consequent establishment of chimerism is a seminal 
event in whole organ allograft acceptance. and the first step 
towards subsequent induction of donor-specific nonreactiv-
ity. I-to Because the migratory interstitial cells are of hema-
tolymphoid origin. the next logical attempt was to augment 
this natural phenomenon by mfusing donor bone marrow 
cells at the time of whole organ transplantation. 
The goal of this study was to induce a higher level of • 
chimerism in unmodified recipients of liver. kidneys. heart. 
Jnd pancreatic islets by perioperative infusion of unaltered 
bom: marrow from the same donor. in an attempt to either 
enhance graft survival andior decrease or ultimately elimi-
nate the requirement for chronic nonspecific immunosup-
pression. 
MATERIALS AND METHODS 
Patients 
Sixteen pallents were simultaneousl" tran~planted with donor hone: 
marrow ~nd "ariou~ other organs (Table 1). Immcdiau:ly following 
whole organ transplantation. and Without c"lOreduction or total 
lymphOid Irradiation (TLl) of the rcclpient. unmodified donor 
hone marrow eelb (.< x 1O'lkg h(ldl" wClght) were mfused through 
a central IV line. Additionally. in three type I diahetic patients. 
donor pancreatic Islets (5.7 x 10' - 1.5 x 10" islets/recipIent) 
isolated hy a modification of the automated method' were infused 
intraporlallv after !!raft placement and pnor to hone marrow 
infusion. 
Immunosuppression 
All patients were maintained on routine immunosuppression with 
FK S06 and prednisone. The FK SOn dosagc was targeted to plasma 
trough levels of 1.5 to 2.0 ng/mL in the tirst postoperative month. 
and O.n to 1.2 n!!lmL thereafter and adjustments madc as indicated 
hy side effects and/Or rejection. Episodes of acute rejections were 
treated with an III increase in FK S06 or a sterOId cycle of 
solumedrol (I !! tapered to 20 mg). whereas. azathIOprine. and 
OKT3 were added to treat recalcitrant rejection episodes. 
Determination of Chimerism 
The presence of donor cells in the recipients' peripheral hlood 
mononuclear cells (PBMC) was evaluated weekly in the tirst month 
after transplantation and monthh' thereafter by the following 
techniques. 
Flow CytomCIT\'. Using donor or recipient-specific fluorescein 
isothiocyanate (FITC)-conjugated anti-HLA class I or class II 
monoclonal antibodies (Mab). single color FACS'" analysis was 
Table 1. Demographic Profile of Bone Marrow and Whole 
Organ Transplant Recipients 
Male 
Female 
Male - Female Transplants 
Mean Age [y] 
Follow-up [range] 
Organs Transplanted 
liver 
Liver ... Pancreatic Islets 
Kidney 
Kidney - Pancreatic Islets 
Heart 
HLA Matches (X :: SOl' 
liver 
Kidney 
Crossmatch Posilive 
'Of a pOSSible of SIX. 
ReCIpients 
(n: 16) 
8 
8 
4 
46 
148-471 
5 
1 
7 
2 
0.37 ::': 0.4 1 
1.72 ::': 1.81 
1/16 
performed. Frequenc\' of acquired cells <(I.S,!' was considered 
helow the detection threshold or unquantifiahlc. 
FluorcsccllI 111 Situ H\'hntiizQliol1 (FISH). Cytocentrifuge prepa-
ration of PBMC ohtained from four female reCIpients of male 
lIfgans were hyhndized \\'Ith hiotinylated Y -chromosome specific 
prohe. which was visualized hy FITC-conjugated avidin. 
Poll'merasc CIlai" Rmclioll (PCR). Donor DNA was detected in 
the reCipient's PBMC b\ P(,R. a procedure descrihed previously.' 
Additionally. donor DNA was also quantitated hv competitive PCR 
(cPCR) in four female recipients of male organs hv a previously 
descrihed technique: 
Immune MOl1ltnring III Vitro. Recipients' PBMCs were used to 
monitor their in vitro immune reactivity prior to transplantation 
and monthly thereafter to mitogens (ConA & PHA). recall anti-
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Table 2. GVH Reactions in Two Patients Receiving Simultaneous Liver and Bone Marrow Transplantation 
Graft vs Host Reaction' 
Case No. POD Grade 
54 lit: 
21 <I 
74 <I 
'Asymptomatic skin rashes without any other organ Involvement. 
tShe is currently on 6mglday of FK506 and no Prednisone. 
j:Maculopapular skin rash Involving 25-50% of body. 
§She is currently on 8 mglday of FK506 and no Prednisone. 
~fMiid rash Involving the skin of one or the other lower leg. 
gens (tetanus toxoid). mixed leukocyte reactions (MLR). and 
cell-mediated Iymphocytotoxicity EC~iF assays. 
RESULTS AND DISCUSSIONS 
The infusion of donor bone marrow cells was uneventful in 
all patients and all allografts are functioning well. Steroids 
have been discontinued in five of SLX liver and three of seven 
kidney recipients. whereas the remainder of the patients are 
on a weaning protocol. All patients are currently being 
maintained on FK 506 (ranging from 2 to 23 mgJd) and the 
two kidney and pancreatic islet recipients are also receiving 
additional immunosuppression with azathioprine (75 mg'd). 
All patients have evidence of circulating donor cells for 
up to 16 months after transplantation by either flow cytom-
etry. peR. or FISH. Only two liver recipients exhibited 
asymptomatic graft vs. host involvement of the skin. which 
in one regressed spontaneously. whereas in the other. it 
required a slight increase in her routine immunosuppres-
sion (Table 2). Allografts of 10 of 16 recipients also 
underwent mild to moderate rejection episodes. which in 
each case was completely resolved by treating with a gram 
of steroids followed by a recycle or in one case with an 
additional course of OKT3. 
Nine of the 16 recipients. in whom interpretation of in 
vitro immune testing was possible. exhibited evolving do-
nor-specific hyporeactivity as early as 50 days after trans-
Treatment 
(mg dO') 
Prednisone 
(7.5 i 15) 
No treatment 
No treatment 
Outcome 
All rash was gone 
within 3 weeks 
All rash was gone 
within 1-2 weeks 
All rash was gone 
within 1-2 weeks 
plantation. which in most cases was sustained for up to the 
last sample tested (POD 225). 
It is too early to predict the impact of donor bone marrow 
cell augmentation on either allograft survival or on our 
capacity to wean and/or eventually withdraw immunosup-
pression. Nevertheless. perioperative infusion of bone mar-
row was safe. which in each recipient resulted in the 
establishment of ·'macrochimerism." Furthermore. serial in 
vitro monitoring data suggest that simultaneous infusion of 
bone marrow along with the whole organ confers an 
advantage to these patients. for the majority of them exhibit 
evolving donor-specitic hyporeactivity. 
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